Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Multiple sclerosis imaging


Published on

  • Be the first to comment

Multiple sclerosis imaging

  1. 1. Multiple Sclerosis Imaging
  2. 2. Clinical <ul><li>Onset </li></ul><ul><ul><li>20 to 35 year old in female </li></ul></ul><ul><ul><li>35 to 45 year old in male </li></ul></ul><ul><ul><li>rare before 14 or after 60 year old </li></ul></ul><ul><li>70 to 75% of patients are female </li></ul><ul><li>Prevalence </li></ul><ul><ul><li>female:male 2:1 </li></ul></ul><ul><ul><li>more common in white </li></ul></ul><ul><li>Genetic: </li></ul><ul><ul><li>first degree relative 10-20X increased risk </li></ul></ul>
  3. 3. Poser Criteria (1983) <ul><li>  Clinically definite MS </li></ul><ul><ul><li>2 attacks and clinical evidence of 2 separate lesions </li></ul></ul><ul><ul><li>2 attacks, clinical evidence of one and paraclinical evidence of another separate lesion </li></ul></ul><ul><li>Laboratory supported Definite MS </li></ul><ul><ul><li>2 attacks, either clinical or paraclinical evidence of 1 lesion, and CSF immunologic abnormalities </li></ul></ul><ul><ul><li>1 attack, clinical evidence of 2 separate lesions & CSF abnormalities </li></ul></ul><ul><ul><li>1 attack, clinical evidence of 1 and paraclinical evidence of another separate lesion, & CSF abnormalities </li></ul></ul><ul><li>Clinically probable MS </li></ul><ul><ul><li>2 attacks & clinical evidence of 1 lesion </li></ul></ul><ul><ul><li>1 attack & clinical evidence of 2 separate lesions </li></ul></ul><ul><ul><li>1 attack, clinical evidence of 1 lesion, and paraclinical evidence of another separate lesion </li></ul></ul><ul><li>Laboratory supported probable MS </li></ul><ul><ul><li>2 attacks & CSF abnormalities </li></ul></ul>
  4. 4. Clinical Types <ul><li>Asymptomatic </li></ul><ul><li>Symptomatic </li></ul><ul><ul><li>85% start out as relapsing remitting. </li></ul></ul><ul><ul><ul><li>About 10% remains benign at 20 years </li></ul></ul></ul><ul><ul><ul><li>55% RR-MS: Relapsing remitting MS - attacks occurring average once per year </li></ul></ul></ul><ul><ul><ul><li>30% SP-MS: Secondary Progressive MS </li></ul></ul></ul><ul><ul><ul><li>About 50% of RR-MS will become SP-MS. </li></ul></ul></ul><ul><ul><li>10-15% starts as progressive disease. </li></ul></ul><ul><ul><ul><li>10% PP-MS: Primary progressive MS. Most commonly first develop symptom at age 40-60. 5% PR-MS: Progressive relapsing </li></ul></ul></ul>
  5. 5. Prognosis <ul><li>Overall prognosis of untreated MS at fifteen years (Minden et al 1993; Weinshenker 1995). </li></ul><ul><ul><li>70 to 80%: of patients have impaired ability to work </li></ul></ul><ul><ul><li>50% need an assistive device to walk </li></ul></ul><ul><ul><li>30%: are wheelchair bound  </li></ul></ul><ul><li>Better for female, and those with predominantly sensory symptoms </li></ul><ul><li>Kurtzke 5 year rule: absence of significant motor or cerebellar dysfunction at 5 years correlates with limited disability at 15 years. </li></ul><ul><li>MS is active in most patients </li></ul><ul><li>Only a small minority have true benign disease </li></ul><ul><li>Disease abnormalities are widespread and clinically underestimated </li></ul>
  6. 6. MRI in MS <ul><li>MRI findings that strongly suggestive of MS </li></ul><ul><ul><li>4 or more white matter lesions (each > 3mm) </li></ul></ul><ul><ul><li>3 white matter lesions, 1 periventricular Lesions </li></ul></ul><ul><ul><li>6 mm diameter or greater </li></ul></ul><ul><ul><li>Ovoid lesions, oriented perpendicular to ventricles </li></ul></ul><ul><ul><li>Corpus callosum lesions </li></ul></ul><ul><ul><li>Brainstem lesions </li></ul></ul><ul><ul><li>Open ring appearance of gadolinium enhancement </li></ul></ul>
  7. 7. Diagnosis MR <ul><li>Supportive </li></ul><ul><ul><li>3-4 scattered lesion without mass effect throughout white matter </li></ul></ul><ul><li>Specific </li></ul><ul><ul><li>>6mm </li></ul></ul><ul><ul><li>Oval shape in parasagital region </li></ul></ul><ul><ul><li>Infratentorial and spinal </li></ul></ul>
  8. 8. Methods <ul><li>Gadolinium </li></ul><ul><ul><li>BBB breakdown </li></ul></ul><ul><li>PD </li></ul><ul><ul><li>Inflammation </li></ul></ul><ul><li>T2 </li></ul><ul><ul><li>Established lesion </li></ul></ul><ul><li>MRS </li></ul><ul><ul><li>Loss of NAA for DD </li></ul></ul><ul><li>Magnetization transfer imaging </li></ul><ul><ul><li>Lesion in otherwise normal appearing white matter </li></ul></ul>
  9. 9. Prognosis Sensitivity <ul><li>Gad – Twice sensitive than T2 monthly MR (0.1mmol/kg) </li></ul><ul><li>Weekly Gad MR more sensitive </li></ul><ul><li>Spinal imaging </li></ul><ul><li>Triple load Gad (0.3mmol/kg) 70% more sensitive and 50%more new lesions </li></ul><ul><li>Magnetization transfer T1 </li></ul><ul><li>Delayed scanning </li></ul><ul><li>Thinner slices 3mm </li></ul><ul><li>Fast flair 1mm and 3mm 3D increases 30% lesion in sub cortical and cortical lesion. </li></ul>
  10. 10. MRI:Prognostic indicator <ul><li>MRI as a prognostic indicator in clinically isolated syndromes: </li></ul><ul><ul><li>MRI normal at presentation </li></ul></ul><ul><ul><ul><li>5 years follow-up: 6% with clinically definite MS </li></ul></ul></ul><ul><ul><ul><li>10 years follow-up: 10% with clinically definite MS </li></ul></ul></ul><ul><ul><li>MRI with 1.2 cc or greater T2 involvement </li></ul></ul><ul><ul><ul><li>5 years follow-up: 96% with clinically definite MS </li></ul></ul></ul><ul><ul><ul><li>10 years follow-up: 86% with clinically definite MS (some patients in the 5 year cohort not included in 10 year cohort) </li></ul></ul></ul><ul><li>Patients with early, relapsing-remitting MS studied by monthly MRIs over several months </li></ul><ul><ul><li>approximately 70% have at least one enhancing lesion during a 3 month period. </li></ul></ul><ul><ul><li>frequency of contrast enhancing lesion activity fluctuates from month to month. </li></ul></ul>
  11. 11. CSF in MS <ul><li>Cell count: </li></ul><ul><ul><li>RBC usually none. </li></ul></ul><ul><ul><li>WBC: 1/3 has 5 to 50 lymphocytes </li></ul></ul><ul><li>Protein: 1/4 of patients has mild elevation </li></ul><ul><li>Myelin basic protein: </li></ul><ul><ul><li>presence indicates demyelination </li></ul></ul><ul><ul><li>can be found in first 2 weeks after a substantial exacerbation in 50-90% of patients </li></ul></ul><ul><ul><li>can be seen in other neuro disease, such as infarct, infection etc </li></ul></ul><ul><li>Immunoglobulin: IgG synthesis rate </li></ul><ul><ul><li>Indicates activity of Plasma cells </li></ul></ul><ul><ul><li>>3 in 80-90% of MS </li></ul></ul><ul><ul><li>elevated in 12% of normal individual, and 30-50% of CNS infections </li></ul></ul><ul><li>Immunoglobulin: IgG index </li></ul><ul><ul><li>>0.7 in 86-94% of MS first CSF abnormality in early MS </li></ul></ul><ul><li>Oligoclonal bands </li></ul><ul><ul><li>present in over 90% of definite MS </li></ul></ul><ul><ul><li>seen in other inflammatory diseases </li></ul></ul><ul><ul><li>seen in 7% of normal control </li></ul></ul>
  12. 12. Evoked potential 70 40 30 BAEP 80 70 50 SSEP 85 60 40 VEP definite MS probable MS possible MS % prolonged in
  13. 13. Clinical correlation <ul><li>Kurtzke Expanded disability status scale (KDSS) </li></ul><ul><ul><li>Subjective </li></ul></ul><ul><ul><li>Poor reproducibility </li></ul></ul><ul><ul><li>Lack of representation of all facets of functional impairment </li></ul></ul><ul><ul><li>Insensitive to change </li></ul></ul><ul><ul><li>No correlation with MR </li></ul></ul><ul><li>Locomotor disability scale reflects spinal cord involvement </li></ul><ul><li>Neuropsychological scale better correlation </li></ul>
  14. 14. Lesion extent <ul><li>Poor correlation between lesion load and EDSS </li></ul><ul><li>Total extent of brain lesion correlate only moderately with locomotor disability </li></ul><ul><li>Clinically isolated syndrome on Brain stem better correlation </li></ul><ul><li>No of brain lesion in MR predicts progress to definite MS in next 1-5years, Poor correlation in next 5years (5-10) </li></ul>
  15. 15. Lesion site <ul><li>Locomotor disability correlate with spinal and post fossa lesion </li></ul><ul><li>T2 lesion load in post fossa and spinal cord do not correlate with EDSS </li></ul><ul><li>Asymptomatic cord lesion with isolated optic neuritis in 40% cases </li></ul><ul><li>Extensive lesion in clinically eloquent pathway without functional consequence </li></ul>
  16. 16. Pathologic nature <ul><li>Acute lesion </li></ul><ul><ul><li>inflammation (perivascular lymphocytes, macrophage, infiltrate edema, active myelin breakdown and axonal damage) </li></ul></ul><ul><li>Subacute lesion </li></ul><ul><ul><li>Variable remyelination </li></ul></ul><ul><li>Chronic lesion </li></ul><ul><ul><li>Complete demyelination with marked astrocytic gliosis, and axonal loss </li></ul></ul><ul><ul><li>Inflammation at the edege </li></ul></ul>
  17. 17. Acute lesion <ul><li>Correlates with Gad enhancement in RR and SP MS for 2-6weeks </li></ul><ul><li>More common during relapse than remission </li></ul><ul><li>Most of them are asymptomatic </li></ul><ul><li>Cord lesion are symptomatic </li></ul><ul><li>Optic nerve lesion correlates with visual loss </li></ul>
  18. 18. Subacute lesions <ul><li>Magnetizing transfer imaging </li></ul><ul><li>T1 hypointense lesion </li></ul><ul><li>MR spectroscopy </li></ul><ul><li>Measurement of atrophy </li></ul><ul><li>Diffusion tensor imaging </li></ul><ul><li>Myelin imaging by T2 decay analysis </li></ul>
  19. 19. Normal appearing White matter with microscopic changes <ul><li>T1, T2 MT ratio and NAA </li></ul><ul><li>Clinical importance not clear </li></ul>
  20. 20. Cortical pathology and synaptic adaptation <ul><li>Synaptic adaptation by functional MR </li></ul><ul><li>Cortical plaque not yet studied </li></ul>